Health on MSN

4 factors that affect your transthyretin amyloidosis (ATTR) prognosis

Medically reviewed by Angela Ryan Lee, MD Transthyretin amyloidosis (ATTR) prognosis can vary based on several factors, including the type you have, how early you were diagnosed, whether you have ...
Verywell Health

The Rare Heart Condition That's Often Mistaken for Normal Aging

Heart failure is a condition that many people face with age, but cases of a rare heart condition tied to a genetic mutation are on the rise. Learn what transthyretin amyloid cardiomyopathy (ATTR-CM) ...
Seeking Alpha

Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (Downgrade)

Intellia Therapeutics is rated "Hold" due to uncertainty from a dosing pause in its MAGNITUDE program for ATTR amyloidosis, but continued advancement in HAE with lonvo-z. Company paused patient dosing ...
Mint

Intellia pauses Phase 3 CRISPR trial as patient develops serious liver reaction to therapy called nex-z

Intellia Therapeutics has temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z, a CRISPR-based therapy for transthyretin amyloidosis with ...
The New England Journal of Medicine

Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy

Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin ...